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We report a case of a female with stage I inﬁltrating ductal carcinoma who received adjuvant therapy including trastuzumab. One
year later she developed lytic lesions and was retreated with trastuzumab that was held after she developed symptomatic heart
failure. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy. After
complications necessitated multiple hospitalizations, a further workup revealed that the lytic lesions were not metastatic breast
cancer but multiple myeloma. Her advanced multiple myeloma was associated with systemic amyloidosis involving gut and heart,
which ultimately led to her demise. This report addresses the pitfalls of overlapping symptoms and the question of which patients
with suspected metastatic disease should undergo a biopsy.
1.CaseReport
A 63-year-old white female was diagnosed with stage 1
inﬁltrating ductal carcinoma at an outside hospital in August
2005. Her tumor was 1cm in size and was ER/PR/Her2Neu
positive with an oncotype score of 29. Axillary lymph node
sampling revealed 0/6 positive lymph nodes. She underwent
adjuvant treatment with epirubicin, cyclophosphamide, and
trastuzumab later that year. At that time she had no clinical
signs of congestive heart failure (CHF). In January 2007,
she developed pain in her sternum and back, and X-
rays revealed multiple small lytic lesions. The diagnosis
of metastatic breast cancer was made and she underwent
radiation therapy to the symptomatic lesions as well as
further trastuzumab treatment for metastatic disease. She
did not receive hormones at the time of diagnosis of
presumed relapse. Soon after start of adjuvant therapy,
she developed symptomatic CHF and was found to have
a left ventricular ejection fraction of 15%. The patient
was diagnosed empirically with trastuzumab-induced car-
diomyopathy at an outside hospital and was started on
diuretics. After a time in rehab, she improved and went back
home.
In February 2008, she presented to our institution for
a second opinion regarding metastatic breast cancer treat-
ment. Because she was dehydrated and lightheaded she was
admitted. The patient was diagnosed with renal failure with
a creatinine above 3mg/dL. Her work-up also included
serum and urine protein electrophoresis. Both demonstrated
a monoclonal gammopathy. She was noted to have 3.5gm
of protein on a 24-hour urine collection and both the urine
and serum immunoﬁxation demonstrated an IgG kappa
monoclonal protein with a serum M-spike of.88gm/dL. Her
serum free light chains revealed a serum free kappa of
8300mg/L with a kappa/lambda ratio of 418. Quantitative
immunoglobulins were normal, Beta-2 microglobulin was
15.6mg/L and calcium was normal.
The inpatient hematology service was asked to com-
ment on the seemingly unusual constellation of diagnoses:
metastatic breast cancer, trastuzumab-induced cardiotoxi-
city, and a new diagnosis of multiple myeloma. She was
noted to have bilateral pleural eﬀusions, pedal edema, and
nausea. Complaints of back pain led to the discovery of
multiple thoracic compression fractures. Because of back
pain and concern for cord instability, she underwent T5,
T6, and T7 corpectomy with reconstruction. Pathologic2 Journal of Oncology
evaluation of the resected bony fragments revealed no
breast tumor cells, while some plasma cells were detected.
There was not enough tissue to adequately evaluate for
plasma cell clonality by immunohistochemistry. A bone
marrow biopsy revealed clonal kappa light chain restricted
cells comprising 30% of the total cells consistent with
a diagnosis of multiple myeloma. Cytogenetics revealed
monosomy 13. A bone survey showed progressing lytic
lesions and a CT guided biopsy of a sacral lesion was
performed that revealed numerous atypical plasma cells
that stained positive for CD138 and negative for pankeratin
consistent with a plasma cell neoplasm. She was there-
fore staged III in the International staging system (ISS),
and stage IIIB in the Durie-Salmon staging system with
extensive bone disease and was started on thalidomide,
dexamethasone, and bortezomib with consideration for
autologous hematopoietic stem cell transplant in the future
depending on improvement of her performance status. After
receiving her ﬁrst dose of thalidomide, dexamethasone,
and bortezomib, she required admission to the hospital
for shortness of breath and was noted to have worsen-
ing bilateral pleural eﬀusions. While admitted she also
complained of persistent nausea. A gastric emptying scan
revealed emptying of 138 minutes (normal less than 110).
An echocardiogram revealed both left ventricular wall and
septal wall thickness. Her septal thickness measured 1.5cm
(normal 0.7–1.2cm). Additional ﬁndings included multiple
areas of hypokineses, dilated inferior vena cava and right
atrium felt by the echo-cardiographer to be consistent with
amyloid heart disease. While hospitalized she had persistent
pedal edema, pleural eﬀusions, anasarca, and subsequent
hypotension with diuretic use. She was treated for a time
with milrinone without appreciable change. Eventually the
decision was made to change the direction of her care to
comfort. She was discharged to a hospice closer to her
home.
2. Discussion
This case prompts an interesting question: which patients
with suspected metastatic disease do you biopsy? Clayer and
Duncan [1] attempted to answer that question by following
50 patients with localized carcinoma who presented with
new bony lesions. In 9 patients (15%) the new bony
lesions were diﬀerent from the primary tumor. Two of
those nine cases were found to have multiple myeloma, one
patient breast cancer, and another melanoma as the primary
tumor.
Given that there are no clear guidelines about which
patients and which tumors require biopsy for veriﬁcation of
metastases, each diagnosis of metastasis should be carefully
evaluated for the likelihood of association with the primary
tumor. Factors that may help decide whether the metastasis
might have arisen from a secondary malignancy include
the age of the patient, the underlying biology of the
primary, the site, grade and radiographic characteristics of
the metastatic lesion, the stage and grade of the primary, and
tumor markers.
In our case advanced multiple myeloma of the patient
was likely associated with amyloidosis of the gut which led
to her persistent nausea and delayed gastric emptying, and
amyloid deposition of the heart which ultimately led to her
demise. The premature assumption of trastuzumab-induced
cardiomyopathyimpededquestioningthelikelihoodofother
reasons for CHF. In retrospect, it may not have been the
trastuzumab that contributed to her cardiomyopathy during
treatment of her presumed breast cancer recurrence, but
ratheramyloidosisinvolvingtheheartandgut.Inaccordance
with that are ﬁndings of the HERA study in which only 1.7%
of the trastuzumab-treated patients developed symptomatic
CHF [2]. This is similar to results of cardiotoxicity in 2%
of women who received trastuzumab as a single agent for
metastatic disease reported by Vogel et al. [3].
In order to provide an optimal treatment for metastatic
disease, it is important to determine the likelihood of the
origin of metastasis. While hypercalcemia and anemia are
common in both diseases, the M-spike on the serum protein
electrophoresis was the ﬁrst indication that her lytic lesions
were due to myeloma and not to breast cancer. In this
case, a careful analysis of existing blood work might have
provided valuable hints, such as elevated protein, for further
diagnosticsteps.Elevatedproteininbloodorurineshouldbe
furtherevaluated by serum and urine protein electrophoresis
as well as free serum light chain ratio. Additionally, if
there is extensive skeletal disease on standard X-rays with
concomitant normal bone scans, multiple myeloma should
be considered. While breast cancer metastases can have
blastic and lytic lesions, myeloma bone lesions are purely
osteolytic due to increased osteoclast activity and suppressed
osteoblast activity [4]. Radiotracer is taken up only by
activated osteoblasts and as such, bone scans are quite
often negative even with extensive skeletal involvement by
myeloma [5]. Bone-speciﬁc alkaline phosphatase in serum
is an indicator of osteoblast activity [4]. Therefore, low
levels of bone-speciﬁc alkaline phosphatase associated with
high levels of bone resorption markers such as C-telopeptide
(CTX) and N-telopeptide (NTX) are suggestive for myeloma
bone lesions.
In addition biopsies are important to provide opti-
mal management of breast cancer patients with distant
metastases. Patients with metastatic progression of local
malignancies can acquire genetic defects that might alter the
treatment plan. Speciﬁcally, in patients with breast cancer,
the appropriate treatment varies according to both ER and
Her-2-Neu receptor status. Simmons et al. noted a high
discordance rate in 29 patients who underwent biopsy of
metastaticlesions.Thediscordanceratebetweentheprimary
and the metastatic site was 40% for hormonal status and 8%
for Her-2-Neu status, changing the treatment plan in 20% of
those patients [6, 7].
Taken together, this case emphasizes that it is essential to
thoroughly analyze the likelihood of the origin of metastasis
in each patient. To provide an optimal treatment for
metastatic disease, biopsy should be considered unless abso-
lutely contraindicated and a careful diﬀerential diagnosis
should be generated and investigated if a biopsy is not
possible.Journal of Oncology 3
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